{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-028343","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.880077+00:00","generated_at":"2026-05-26T02:23:26.796729+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cullinan Therapeutics reports Q4/FY 2024 results; zipalertinib pivotal study met endpoint","bullets":["Cash and investments of $606.9M at Dec 31, 2024; runway extended into 2028.","Net loss of $47.6M in Q4 2024 (vs $23.8M Q4 2023); FY 2024 net loss $167.4M (vs $153.2M).","R&D expenses $40.5M Q4 2024 (vs $34.8M); G&A $14.6M (vs $10.6M) year-over-year.","Zipalertinib Phase 2b met primary endpoint (ORR); full results mid-2025; NDA submission planned H2 2025.","Initial CLN-978 SLE data expected Q4 2025; CLN-619 endometrial/cervical cancer data expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-028343","json":"https://secwatch.observer/filing/0000950170-25-028343.json","markdown":"https://secwatch.observer/filing/0000950170-25-028343.md","text":"https://secwatch.observer/filing/0000950170-25-028343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000095017025028343/0000950170-25-028343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000095017025028343/cgem-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:23:26.796729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}